Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized neoantigen-specific TCR-T cells for advanced solid cancers
NL-OMON59823Phase 1Completed
- Sponsor
- Neogene Therapeutics
- Start
- Apr 2022
- Countries
- 1
01
Overview
Phase 1, open-label trial in Non-hematologic malignancy, sponsored by Neogene Therapeutics. Primary endpoint: Primary endpoint(s). Started Apr 2022; status: completed.
02
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on NL-OMON59823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59823.